Previous 10 | Next 10 |
– Study demonstrated objective response rates of 38% in all patients, 62.5% in patients with renal cell carcinoma and 42.4% in patients with urothelial carcinoma – – Data to be presented during the 2021 American Society of Clinical Oncology’s ...
Image source: The Motley Fool. Exelixis Inc (NASDAQ: EXEL) Q4 2020 Earnings Call Feb 10, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Exelixis Inc (EXEL) Q4 2020 Earnings Call Transcript
Exelixis, Inc. (EXEL) Q4 2020 Earnings Conference Call February 10, 2021, 5:00 PM ET Company Participants Susan Hubbard - Executive Vice President-Public Affairs and Investor Relations Mike Morrissey - President and Chief Executive Officer Chris Senner - Chief Financial Officer Peter Lamb - C...
The following slide deck was published by Exelixis, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Exelixis, Inc. 2020 Q4 - Results - Earnings Call Presentation
Exelixis (EXEL): Q4 Non-GAAP EPS of $0.14 beats by $0.09; GAAP EPS of $0.09 beats by $0.04.Revenue of $270.1M (+12.4% Y/Y) beats by $8.66M.Shares +0.3%.Press Release For further details see: Exelixis EPS beats by $0.09, beats on revenue
- Total Revenues of $270.1 Million for the Fourth Quarter of 2020, $987.5 Million for the Full Year 2020 - - GAAP Diluted EPS of $0.09 for the Fourth Quarter of 2020, $0.35 for the Full Year 2020 - - Non-GAAP Diluted EPS of $0.14 for the Fourth Quarter of 202...
- Online event will be accessible at www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) will host an investor briefing to discuss data presented at the American Society of Clinical Oncology’s 2021 Genitourinary Cancers Symposium (ASCO GU 2021). The online-only e...
Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (EXEL) disclosed new data for Opdivo/ Cabometyx combo in a pivotal Phase 3 trial for the first-line treatment of advanced renal cell carcinoma.The trial sponsored by Bristol Myers Squibb and Ono Pharmaceutical (OPHLF) and co-funded by Exelix...
– Results of retrospective analysis demonstrate a 61% intracranial response rate in patients with progressing brain metastases – – Data to be presented during the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Symposium ...
With a median follow-up of two years, OPDIVO in combination with CABOMETYX continues to demonstrate superior progression-free survival, overall survival and objective response rate compared to sunitinib Patients treated with OPDIVO in combination with CABOM...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...